Skip to main content
. 2011 Oct 21;16(11):1535–1546. doi: 10.1634/theoncologist.2011-0165

Table 3.

Retrospective studies evaluating clinical prevalence of PTEN loss and PIK3CA mutations in HER-2+ breast cancer primary tissue samples and response to trastuzumab

graphic file with name onc01111-0901-t03.jpg

Studies involving breast cancer cell lines or tumor samples unspecified for HER-2 overexpression are not included in this table. PTEN expression was determined by immunohistochemistry and semiquantified by IRS, the product of the percentage of PTEN+ cells (scored 0–4) and PTEN staining intensity (scored 1–3).

Tumor DNA was polymerase chain reaction amplified and directly sequenced in all studies.

Single nucleotide polymorphism–based sequencing was also performed in the Berns et al. [21] study.

aSome studies included both HER-2-positive and -negative patients. Only data on HER-2-positive patients are presented in this table.

Abbreviations: HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; IRS, immunoreactive score; NA, not available; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue deleted on chromosome ten; RR, response rate; T, trastuzumab; TTP, time to progression.